Physician profile
Natalia E Veselova
NPI 1023058377
$11,495.20
in general payments reported to CMS, 2019-2025
33 companies · $2,137 in 2025
The $2,137 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $940 · 2020: $2,192 · 2021: $795 · 2022: $2,391 · 2023: $1,608 · 2024: $1,431 · 2025: $2,137.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,724 · Education: $452.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,724.29 |
| Education | $451.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $3,849.41 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Horizon Therapeutics Plc | $1,548.40 | 2019-2023 | Krystexxa |
| Abbvie INC. | $1,016.50 | 2019-2025 | Rinvoq, Skyrizi |
| Amgen INC. | $916.50 | 2020-2025 | Enbrel, Evenity, Tavneos |
| Ucb, INC. | $661.57 | 2019-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $635.43 | 2019-2025 | Taltz |
| Mallinckrodt Hospital Products INC. | $456.05 | 2021-2025 | Acthar |
| Pfizer INC. | $396.08 | 2019-2024 | |
| Genentech USA, INC. | $372.25 | 2019-2025 | Actemra, Rituxan |
| Glaxosmithkline, LLC. | $320.87 | 2022-2025 | Benlysta |
| Radius Health, INC. | $206.64 | 2019-2025 | Tymlos |
| Actelion Pharmaceuticals US, INC. | $168.29 | 2022-2025 | Uptravi, Opsumit |
| Ani Pharmaceuticals, INC. | $152.84 | 2023-2025 | Purified Cortrophin Gel |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.50 | 2022 | |
| Organon LLC | $101.65 | 2023-2025 | Renflexis, Hadlima |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $75.66 | 2023-2024 | Lupkynis |
| Novartis Pharmaceuticals Corporation | $71.28 | 2024-2025 | |
| Genzyme Corporation | $61.80 | 2023-2024 | |
| Invivyd INC | $52.52 | 2025 | Pemgarda |
| Fidia Pharma USA INC. | $38.11 | 2022-2023 | Hymovis, Triluron |
| Tersera Therapeutics LLC | $31.89 | 2025 | Quzyttir |
| Alexion Pharmaceuticals, INC. | $31.44 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $24.88 | 2024 | Arcalyst |
| Octapharma USA, INC. | $22.86 | 2024 | Octagam Immune Globulin (Human) |
| Kyowa Kirin, INC. | $22.13 | 2025 | |
| Scilex Pharmaceuticals INC. | $21.16 | 2024 | |
| Mallinckrodt Enterprises LLC | $20.94 | 2019 | |
| Depuy Synthes Sales INC. | $19.26 | 2022 | |
| Bioventus LLC | $16.83 | 2021 | |
| Pacira Therapeutics, INC. | $16.56 | 2019 | |
| Merck Sharp & Dohme LLC | $15.01 | 2020 | |
| Ibsa Pharma INC. | $14.49 | 2025 | Flector, Licart, Tirosint |
| Ferring Pharmaceuticals INC. | $11.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natalia Veselova listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.